Pay in 4 interest-free payments of $6.47 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
2 8 12 But those data are confounded by co-administration with semaglutide, so the cagrilintide-specific contribution cannot be cleanly isolated
SURMOUNT-1 results (72 weeks, adults with obesity): 5 mg dose: approximately 15% body weight loss 10 mg dose: 19.5% body weight loss 15 mg dose: 22.5% body weight loss Placebo: 3.1% body weight loss At the 15 mg maximum dose, the average participant lost about 52 pounds over 72 weeks
Mohd KasimVNobleSLiewKTanJIsrafDThamC
Although no head to head trials comparing tirzepatide to semaglutide 2mg exists, an adjusted indirect treatment comparison study aimed to compare these two agents based on the results from SURPASS 2 and SUSTAIN FORTE
Patients often begin to experience reduced appetite and initial weight loss during this phase
